Description of UDS MCI, pre-MCI, and Control Subjects

 
   Lead Investigator:    Ronald Petersen
   Institution      :    Mayo
   E-Mail           :    peter8@mayo.edu
   Proposal ID      :    3


   Publications:


1  Grundman M
   Antioxidant Supplements are Associated with a Lower Risk of Developing Mild Cognitive Impairment or Alzheimer's Disease among Healthy Elderly Volunteers
   Abstract  Neuroscience,546:516,2001,

   PUBLISHED



2  Grundman M
   The Alzheimer's Disease Centers' Neuropsychological Database Initiative: A Resource for Alzheimer's Disease Prevention Trials
   2001   Book Section  In: Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics New York: Wiley , 

   PUBLISHED



3  Ji M, Xiong C, Grundman M
   Hypothesis testing of a change point during cognitive decline among Alzheimer's disease patients
   Journal Article  J Alzheimers Dis,5:375-382,2003,

   PUBLISHED



4  Petersen RC,  Gill DP, Phillips LE , Aisen P
   Early MCI as an Imaging Target: data from the National Alzheimer's Coordinating Center
   Abstract  Alzheimers Dement,6:S58,2010,

   PUBLISHED





   Proposal Description:
   Describe UDS clinical population, focusing on: (1) MCI and its subtypes, (2) whether patients with pre-MCI (not CDR=0) have disproportionate use of medications or unusually high frequency of depressive features that might contribute to their cognitive difficulties (rather than underlying neurodegenerative disease or other factors), (3) controls -- family history, memory complaints.